Cancer Immunotherapy and COVID-19: Mind the Gap

Authors

  • Abhijit Chakraborty Baylor College of Medicine
  • Upasana Roy
  • Abhishek Shankar
  • Aalekhya Biswas
  • Faisal Aziz

DOI:

https://doi.org/10.31557/apjcc.2020.5.S1.213-218

Keywords:

COVID 19, Immunotherapy, Cancer, Cancer Vaccine

Abstract

The urgent need to develop a vaccine to prevent SARS-CoV-2 pandemic is now the main focus all over the world. Over the past decade, scientists and drug industries have been works on different kinds of human threatening disease like H1N1 influenza, Ebola, Zika, SARS-CoV, MERS, etc. The knowledge to work in this area, helping the researcher a lot to develop a vaccine in at Pandemic Speed. However, the development of a new drug and starting application on human heal is a time-consuming manner. It becomes very hard in the case of COVID-19 as the virus characters changing rapidly. Here we discuss whether the anti-cancer immunotherapy could give some hope to protect against COVID-19 and also enrollment of cancer vaccine which started a randomized clinical trial to boost the treatment strategies against COVID-19 on an emergency basis.

Published

2020-08-24

How to Cite

Chakraborty, A., Roy, U., Shankar, A., Biswas, A., & Aziz, F. (2020). Cancer Immunotherapy and COVID-19: Mind the Gap. Asian Pacific Journal of Cancer Care, 5(S1), 213–218. https://doi.org/10.31557/apjcc.2020.5.S1.213-218